Description
BPA CANCELLATION DUE TO CHANGE FROM "PRIME VENDOR FALSE" TO "PRIME VENDOR TRUE"
Base award description: BPA FOR MIRCERA - BASE YEAR WITH FOUR ONE YEAR OPTION PERIODS
Modification chain · 4 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2020-04-29+$0= $0
- Mod P000012020-12-28+$0= $0
- Mod P000022021-03-16+$0= $0
- Mod P000032021-06-02+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2020-04-29 | +$0 | $0 | BPA FOR MIRCERA - BASE YEAR WITH FOUR ONE YEAR OPTION PERIODS |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2020-12-28 | +$0 | $0 | 2021 PUBLIC LAW PRICING UPDATES |
| Mod P00002· EXERCISE AN OPTION | 2021-03-16 | +$0 | $0 | EXERCISE OPTION YEAR 1. |
| Mod P00003· LEGAL CONTRACT CANCELLATION | 2021-06-02 | +$0 | $0 | BPA CANCELLATION DUE TO CHANGE FROM "PRIME VENDOR FALSE" TO "PRIME VENDOR TRUE" |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI R77QQUHCTUP7)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25226N0475 | 252-NETWORK CONTRACT OFFICE 12 (36C252) · 6505 · DRUGS AND BIOLOGICALS | $3,546 | FY2026 |
| 36E79726A0016 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C26126N0435 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $2,730 | FY2026 |
| 36F79726D0092 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C26126N0340 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $228 | FY2026 |
| 36C26126N0323 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $114 | FY2026 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79720A0009_3600 · retrieved 2026-09-26.